-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 9th American Society of Hematology Oncology (SOHO) Annual Meeting will be held in Houston, USA on September 8-11, 2021
.
The SOHO Annual Conference is an international conference on hematological malignancies specially designed for clinicians, research scientists and related health professionals.
This year’s SOHO conference will continue to deliver high-quality content and focus on providing practitioners and practitioners in the field of hematological malignancies.
Scientists provide the latest information
.
A report published at this conference introduced the treatment strategy for Hodgkin’s lymphoma that has failed the treatment of immune checkpoint inhibitors
.
The editor now organizes the main content of the research as follows for the reference of readers
.
Classical Hodgkin's lymphoma (cHL) is uniquely susceptible to PD-1 pathway blockade
.
This may be related to the 9p24.
1 amplification of the PD-1 ligand (PD-L1 and PD-L2) related gene loci possessed by almost all cHL patients
.
The results of a number of phase II clinical studies have shown that although PD-1 monoclonal antibody treatment of relapsed/refractory (R/R) cHL patients has a low complete remission (CR) rate, it can achieve disease remission in about two-thirds of patients
.
In addition, the remission status of these patients can last a long time, with a median duration of remission reaching 1.
5 years
.
The results of these clinical studies make PD-1 monoclonal antibody the cornerstone of treatment for patients with R/R cHL (especially third-line therapy)
.
Although PD-1 monoclonal antibody has excellent efficacy in R/R cHL patients, most patients still have disease progression (PD)
.
Even in patients with CR, more than 50% of patients still develop PD within 2-3 years after PD-1 monoclonal antibody treatment
.
This part of patients usually received ≥ 2 lines of multi-drug chemotherapy and verbutuximab treatment, so the rescue treatment options for this part of patients are limited
.
At present, there is no standard treatment plan for R/R cHL patients after PD-1 monoclonal antibody treatment fails
.
Recent research results suggest that PD-1 monoclonal antibody has a chemotherapy sensitization effect, and that patients treated with PD-1 monoclonal antibody have a better curative effect after receiving chemotherapy
.
Therefore, patients who have failed PD-1 monoclonal antibody treatment, even those who have been refractory to previous chemotherapy, may regain CR after receiving the salvage treatment of conventional chemotherapy
.
There are many treatment strategies for R/R cHL patients with PD after PD-1 monoclonal antibody treatment
.
Most of them are based on the biological development of cHL to explore the combination of immune checkpoint inhibitors, such as CTLA-4 blockers, LAG-3 blockers, and demethylation drugs
.
This type of combination program not only provides a new treatment option for patients after PD-1 monoclonal antibody treatment has failed, but also may serve as a more effective alternative to PD-1 monoclonal antibody single-drug regimen
.
In addition, the latest research results indicate that CD30 chimeric antigen receptor T cell (CAR-T) immunotherapy may also be an effective rescue treatment option for this type of patient
.
In the future, it is necessary for related research to explore whether these treatment options can bring the possibility of curing for patients like hematopoietic stem cell transplantation, while reducing the demand for hematopoietic stem cell transplantation in cHL patients and avoiding related treatment risks
.
Many studies are currently exploring the value of PD-1 monoclonal antibody in the first-line treatment of cHL
.
Although the use of PD-1 monoclonal antibody in the first-line treatment may increase the cure rate and reduce the use of chemotherapy, this treatment strategy will also affect the second-line treatment efficacy of cHL patients after the disease is relapsed and refractory
.
In view of the chemotherapy sensitization effect of PD-1 monoclonal antibody, these patients are more likely to obtain disease remission through subsequent chemotherapy and autologous hematopoietic stem cell transplantation (ASCT)
.
However, for patients with R/R cHL who have failed front-line treatment with PD-1 monoclonal antibody, the prognosis may be worse after PD-1 monoclonal antibody treatment
.
Regardless of the outcome, new strategies for the first-line treatment of cHL patients deserve further exploration
.
The successful results of related studies may completely change the treatment strategy of cHL
.
Reference source: 1.
Philippe Armand, et al.
2021SOHO.
EXABS-110-NHL.
Stamp "read the original text", we make progress together
.
The SOHO Annual Conference is an international conference on hematological malignancies specially designed for clinicians, research scientists and related health professionals.
This year’s SOHO conference will continue to deliver high-quality content and focus on providing practitioners and practitioners in the field of hematological malignancies.
Scientists provide the latest information
.
A report published at this conference introduced the treatment strategy for Hodgkin’s lymphoma that has failed the treatment of immune checkpoint inhibitors
.
The editor now organizes the main content of the research as follows for the reference of readers
.
Classical Hodgkin's lymphoma (cHL) is uniquely susceptible to PD-1 pathway blockade
.
This may be related to the 9p24.
1 amplification of the PD-1 ligand (PD-L1 and PD-L2) related gene loci possessed by almost all cHL patients
.
The results of a number of phase II clinical studies have shown that although PD-1 monoclonal antibody treatment of relapsed/refractory (R/R) cHL patients has a low complete remission (CR) rate, it can achieve disease remission in about two-thirds of patients
.
In addition, the remission status of these patients can last a long time, with a median duration of remission reaching 1.
5 years
.
The results of these clinical studies make PD-1 monoclonal antibody the cornerstone of treatment for patients with R/R cHL (especially third-line therapy)
.
Although PD-1 monoclonal antibody has excellent efficacy in R/R cHL patients, most patients still have disease progression (PD)
.
Even in patients with CR, more than 50% of patients still develop PD within 2-3 years after PD-1 monoclonal antibody treatment
.
This part of patients usually received ≥ 2 lines of multi-drug chemotherapy and verbutuximab treatment, so the rescue treatment options for this part of patients are limited
.
At present, there is no standard treatment plan for R/R cHL patients after PD-1 monoclonal antibody treatment fails
.
Recent research results suggest that PD-1 monoclonal antibody has a chemotherapy sensitization effect, and that patients treated with PD-1 monoclonal antibody have a better curative effect after receiving chemotherapy
.
Therefore, patients who have failed PD-1 monoclonal antibody treatment, even those who have been refractory to previous chemotherapy, may regain CR after receiving the salvage treatment of conventional chemotherapy
.
There are many treatment strategies for R/R cHL patients with PD after PD-1 monoclonal antibody treatment
.
Most of them are based on the biological development of cHL to explore the combination of immune checkpoint inhibitors, such as CTLA-4 blockers, LAG-3 blockers, and demethylation drugs
.
This type of combination program not only provides a new treatment option for patients after PD-1 monoclonal antibody treatment has failed, but also may serve as a more effective alternative to PD-1 monoclonal antibody single-drug regimen
.
In addition, the latest research results indicate that CD30 chimeric antigen receptor T cell (CAR-T) immunotherapy may also be an effective rescue treatment option for this type of patient
.
In the future, it is necessary for related research to explore whether these treatment options can bring the possibility of curing for patients like hematopoietic stem cell transplantation, while reducing the demand for hematopoietic stem cell transplantation in cHL patients and avoiding related treatment risks
.
Many studies are currently exploring the value of PD-1 monoclonal antibody in the first-line treatment of cHL
.
Although the use of PD-1 monoclonal antibody in the first-line treatment may increase the cure rate and reduce the use of chemotherapy, this treatment strategy will also affect the second-line treatment efficacy of cHL patients after the disease is relapsed and refractory
.
In view of the chemotherapy sensitization effect of PD-1 monoclonal antibody, these patients are more likely to obtain disease remission through subsequent chemotherapy and autologous hematopoietic stem cell transplantation (ASCT)
.
However, for patients with R/R cHL who have failed front-line treatment with PD-1 monoclonal antibody, the prognosis may be worse after PD-1 monoclonal antibody treatment
.
Regardless of the outcome, new strategies for the first-line treatment of cHL patients deserve further exploration
.
The successful results of related studies may completely change the treatment strategy of cHL
.
Reference source: 1.
Philippe Armand, et al.
2021SOHO.
EXABS-110-NHL.
Stamp "read the original text", we make progress together
